By Katherine Hamilton
Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients.
The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.
Shares rose 8% to $1.85 in premarket trading Monday.
The drug combination is designed to treat people with recurrent or metastatic head and neck squamous cell carcinoma. Combining the therapies has increased response rates by sevenfold and more than doubled median overall survival compared with historical results. The treatment has no new safety signals, Immutep said.
Immutep has requested a meeting with the Food and Drug Administration to discuss next steps including paths to approval. The company is continuing patient follow-ups, data collection and analysis, and plans to provide a further update later this year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 05, 2025 09:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。